Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meeting… – Press Release

New data highlights include:

– Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransCon^TM hGH

– Initial findings from research on comorbidities associated with adult growth hormone deficiency

COPENHAGEN, Denmark, May 01, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S ASND today announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May. Topics will include new open-label extension data for children with growth hormone deficiency treated with TransCon hGH for 2.5 years; research findings showing comorbidities associated with adult growth hormone deficiency; and presentations of TransCon PTH Phase 2 patient-reported health, quality-of-life, and Week 84 data in adult hypoparathyroidism. Meetings in the United States will also showcase SKYTROFA^® (lonapegsomatropin-tcgd), the Company’s FDA-approved once-weekly treatment for pediatric growth hormone deficiency.

“The flow of data that begins today at the PES annual meeting signifies the growing strength and breadth of our endocrinology rare disease portfolio,” said Dana Pizzuti, M.D., Senior Vice President and Chief Medical Officer at Ascendis Pharma. “We are excited to demonstrate the many areas where we are applying TransCon technology to make a meaningful difference for patients and look forward to interacting with a broad range of endocrinology physicians, nurses, and healthcare professionals virtually and in person in the weeks ahead.”

Ascendis Pharma’s data and research presentations during the month of May are listed below. Registered attendees can find out more details at each event’s website.